vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and NexPoint Real Estate Finance, Inc. (NREF). Click either name above to swap in a different company.
CHAMPIONS ONCOLOGY, INC. is the larger business by last-quarter revenue ($15.0M vs $11.1M, roughly 1.4× NexPoint Real Estate Finance, Inc.). NexPoint Real Estate Finance, Inc. runs the higher net margin — 216.6% vs 1.8%, a 214.8% gap on every dollar of revenue. On growth, CHAMPIONS ONCOLOGY, INC. posted the faster year-over-year revenue change (11.5% vs -48.8%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
NexPoint Real Estate Finance, Inc. is a US-based commercial real estate finance firm that offers structured financing solutions for multifamily, office, industrial, and hospitality properties. It focuses on originating, managing and servicing a diversified portfolio of mortgage loans and real estate-related investments to deliver stable risk-adjusted returns to stakeholders.
CSBR vs NREF — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $11.1M |
| Net Profit | $268.0K | $24.0M |
| Gross Margin | 51.7% | — |
| Operating Margin | 1.2% | — |
| Net Margin | 1.8% | 216.6% |
| Revenue YoY | 11.5% | -48.8% |
| Net Profit YoY | -63.2% | 58.7% |
| EPS (diluted) | $0.02 | $0.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $11.1M | ||
| Q3 25 | $14.0M | $12.5M | ||
| Q2 25 | $12.4M | $12.1M | ||
| Q1 25 | $17.0M | $11.5M | ||
| Q4 24 | $13.5M | $21.7M | ||
| Q3 24 | $14.1M | $12.5M | ||
| Q2 24 | $14.0M | $6.7M | ||
| Q1 24 | $12.0M | $-12.8M |
| Q4 25 | $268.0K | $24.0M | ||
| Q3 25 | $-436.0K | $50.9M | ||
| Q2 25 | $-1.8M | $22.3M | ||
| Q1 25 | $4.5M | $26.0M | ||
| Q4 24 | $728.0K | $15.2M | ||
| Q3 24 | $1.3M | $23.3M | ||
| Q2 24 | $-109.0K | $12.1M | ||
| Q1 24 | $-2.5M | $-14.6M |
| Q4 25 | 51.7% | — | ||
| Q3 25 | 42.9% | — | ||
| Q2 25 | 41.1% | — | ||
| Q1 25 | 61.2% | — | ||
| Q4 24 | 44.9% | — | ||
| Q3 24 | 49.7% | — | ||
| Q2 24 | 48.2% | — | ||
| Q1 24 | 34.7% | — |
| Q4 25 | 1.2% | — | ||
| Q3 25 | -3.8% | — | ||
| Q2 25 | -16.2% | — | ||
| Q1 25 | 26.4% | — | ||
| Q4 24 | 5.4% | — | ||
| Q3 24 | 9.5% | — | ||
| Q2 24 | -1.9% | — | ||
| Q1 24 | -21.4% | — |
| Q4 25 | 1.8% | 216.6% | ||
| Q3 25 | -3.1% | 407.0% | ||
| Q2 25 | -14.9% | 184.5% | ||
| Q1 25 | 26.4% | 225.6% | ||
| Q4 24 | 5.4% | 69.9% | ||
| Q3 24 | 9.3% | 186.4% | ||
| Q2 24 | -0.8% | 179.7% | ||
| Q1 24 | -21.1% | 114.3% |
| Q4 25 | $0.02 | $0.47 | ||
| Q3 25 | $-0.03 | $1.14 | ||
| Q2 25 | $-0.12 | $0.54 | ||
| Q1 25 | $0.31 | $0.70 | ||
| Q4 24 | $0.05 | $0.71 | ||
| Q3 24 | $0.09 | $0.74 | ||
| Q2 24 | $-0.01 | $0.40 | ||
| Q1 24 | $-0.19 | $-0.83 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $31.1M |
| Total DebtLower is stronger | — | $771.2M |
| Stockholders' EquityBook value | $4.2M | $388.0M |
| Total Assets | $30.2M | $5.3B |
| Debt / EquityLower = less leverage | — | 1.99× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $31.1M | ||
| Q3 25 | $10.3M | $17.9M | ||
| Q2 25 | $9.8M | $9.1M | ||
| Q1 25 | $3.2M | $19.2M | ||
| Q4 24 | $2.8M | $3.9M | ||
| Q3 24 | $2.9M | $34.7M | ||
| Q2 24 | $2.6M | $4.3M | ||
| Q1 24 | $4.5M | $13.5M |
| Q4 25 | — | $771.2M | ||
| Q3 25 | — | $720.9M | ||
| Q2 25 | — | $815.6M | ||
| Q1 25 | — | $831.5M | ||
| Q4 24 | — | $799.3M | ||
| Q3 24 | — | $815.5M | ||
| Q2 24 | — | $861.0M | ||
| Q1 24 | — | $843.3M |
| Q4 25 | $4.2M | $388.0M | ||
| Q3 25 | $3.5M | $375.4M | ||
| Q2 25 | $3.8M | $348.2M | ||
| Q1 25 | $5.5M | $343.7M | ||
| Q4 24 | $681.0K | $336.5M | ||
| Q3 24 | $-332.0K | $335.8M | ||
| Q2 24 | $-1.9M | $327.5M | ||
| Q1 24 | $-2.1M | $327.1M |
| Q4 25 | $30.2M | $5.3B | ||
| Q3 25 | $30.5M | $5.3B | ||
| Q2 25 | $32.3M | $5.4B | ||
| Q1 25 | $30.6M | $5.4B | ||
| Q4 24 | $25.2M | $5.4B | ||
| Q3 24 | $24.9M | $5.7B | ||
| Q2 24 | $26.1M | $6.6B | ||
| Q1 24 | $26.8M | $7.1B |
| Q4 25 | — | 1.99× | ||
| Q3 25 | — | 1.92× | ||
| Q2 25 | — | 2.34× | ||
| Q1 25 | — | 2.42× | ||
| Q4 24 | — | 2.38× | ||
| Q3 24 | — | 2.43× | ||
| Q2 24 | — | 2.63× | ||
| Q1 24 | — | 2.58× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $-4.5M |
| Free Cash FlowOCF − Capex | $-2.0M | — |
| FCF MarginFCF / Revenue | -13.1% | — |
| Capex IntensityCapex / Revenue | 1.6% | — |
| Cash ConversionOCF / Net Profit | -6.47× | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $-4.5M | ||
| Q3 25 | $600.0K | $8.1M | ||
| Q2 25 | $6.9M | $3.3M | ||
| Q1 25 | $490.0K | $16.0M | ||
| Q4 24 | $-283.0K | $4.4M | ||
| Q3 24 | $311.0K | $14.7M | ||
| Q2 24 | $-1.8M | $-7.5M | ||
| Q1 24 | $-919.0K | $17.7M |
| Q4 25 | $-2.0M | — | ||
| Q3 25 | $554.0K | — | ||
| Q2 25 | $6.6M | — | ||
| Q1 25 | $448.0K | — | ||
| Q4 24 | $-377.0K | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-1.8M | — | ||
| Q1 24 | $-1.0M | — |
| Q4 25 | -13.1% | — | ||
| Q3 25 | 4.0% | — | ||
| Q2 25 | 53.5% | — | ||
| Q1 25 | 2.6% | — | ||
| Q4 24 | -2.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -13.0% | — | ||
| Q1 24 | -8.4% | — |
| Q4 25 | 1.6% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.7% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.8% | — |
| Q4 25 | -6.47× | -0.19× | ||
| Q3 25 | — | 0.16× | ||
| Q2 25 | — | 0.15× | ||
| Q1 25 | 0.11× | 0.62× | ||
| Q4 24 | -0.39× | 0.29× | ||
| Q3 24 | 0.24× | 0.63× | ||
| Q2 24 | — | -0.62× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
NREF
Segment breakdown not available.
